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Human brown adipose tissue: Underestimated target in metabolic disease?☆
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NUTRIM School of Nutrition and Translational Research in Metabolism, Departments of Nutrition and Human Movement Sciences, Maastricht University, Maastricht, the
Netherlands
A R T I C L E I N F O
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A B S T R A C T
Active brown adipose tissue (BAT) has, since it rediscovery in adult humans in 2009, received much attention for
its ability to increase energy expenditure when activated. By means of mitochondrial uncoupling activity BAT's
main function is to produce heat instead of storing energy such as in white adipose tissue (WAT). Therefore, BAT
is considered a new potential target to treat obesity and the metabolic syndrome. However, the contribution of
this thermogenic tissue is still a matter of debate among researchers.
The aim of this review is to give an overview of the differences between classical brown adipocytes and
inducible beige adipocytes in humans, and the potential activators of BAT in humans. Furthermore newly de-
scribed genetic markers for identification of these two types of brown adipocytes are examined. Finally, the
potential of the current measurement techniques, and the contribution of BAT activity to whole body energy
expenditure are discussed.
1. Introduction
In modern society, energy intake often exceeds energy expenditure.
This in turn leads to obesity, in which excess energy is stored in white
adipose tissue (WAT). Under a microscope, WAT can be recognized by
the presence of a single large lipid droplet and few mitochondria. In
contrast brown adipose tissue (BAT) is characterized by large amounts
of mitochondria and a relatively small capacity of fat storage, and most
importantly is responsible for non-shivering thermogenesis [1]. At least
in animals BAT plays a dominant role in maintaining body temperature
in the cold. The first description of BAT was by Konrad Gessner in 1551,
who described it as ‘as nor flesh nor fat’. In 1985, Himms-Hagen de-
scribed BAT as a tissue containing multilocular adipocytes with mul-
tiple lipid-containing droplets and many mitochondria [2]. The pre-
sence of uncoupling protein 1 (UCP1 aka thermogenin) in the
mitochondria of BAT enables heat production. UCP1 uncouples the
proton gradient of the electron transport chain that would normally be
used to generate ATP, thus resulting in heat production [1].
In newborns of precocial species such as deer and lamb BAT is
predominantly found in the perirenal fat deposit, while in rodents, and
human newborns, it is mainly found in the interscapular area, as well as
in cervical, para-aortal and subcostal area [2]. In early studies by
Huttunen et al. in 1981 and by Heaton in 1972 brown adipocytes were
seen in multiple adipose tissue depots in human subjects, in several age
categories [3,4]. Nevertheless, the assumption was that in humans BAT
dissipates with age and interest in BAT was diminished. However in
2007, Nedergaard et al. reviewed nuclear imaging studies in humans
that showed that the uptake of 18F–FDG (glucose) in the neck and
shoulder region, was by brown adipose tissue [5]. Then in 2009, three
independent research groups identified functional cold activated BAT in
adult humans [6–8] igniting the discussion of its importance in human
physiology and metabolism. Since then studies on BAT increased dra-
matically, although the amount of well-controlled intervention studies
in humans is relatively scarce compared to number of animal studies,
cell studies and retrospective studies. The importance and contribution
of human BAT in whole body metabolism is still not understood despite
this strong revival of studies on BAT [9,10]. In this review we will first
discuss different types of thermogenic and UCP1-positive adipocytes.
Next, we will discuss different ways to activate and measure BAT ac-
tivity. Finally, we will examine the potential role of human BAT activity
in relation to whole body metabolism and energy expenditure to pre-
vent and/or treat obesity and the metabolic syndrome.
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2. Defining the brown adipocyte
2.1. Brown adipocytes vs. beige/brite adipocytes
In order to understand the role of BAT at whole body level, we first
need to examine what defines brown adipocytes. Presence and activa-
tion of uncoupling protein 1 (UCP1) in BAT is crucial for its function to
produce heat. UCP1 is located in the inner membrane of mitochondria
where it influences the proton gradient in oxidative phosphorylation.
Normally oxidative phosphorylation generates ATP via the proton
gradient that is present between the mitochondrial matrix and the
mitochondrial intermembrane space. However, when activated, UCP1
uncouples the proton gradient from ATP-synthase thereby generating
heat instead of ATP. Cold is the most effective way to activate BAT.
Cold exposure stimulates thermoreceptors in the skin, which in turn
activate neurons in the ventromedial nucleus of the hypothalamus,
leading to the release of norepinephrine [1,11]. The importance of the
sympathetic nervous system is shown in studies with pharmacological
blockade of adrenergic receptors, or lesions in the ventromedial nucleus
in animals [12,13]. In one such study, injections with glutamate into
the ventromedial nucleus in mice induced a dose-dependent stimulation
of interscapular BAT [12], while another study showed that β-blockade
via propranolol results in reduced BAT activity [13].
Norepinephrine binds the β3 adrenergic receptor on the brown
adipocyte thereby activating the intracellular signalling cascade. Via
second messenger cyclic AMP, activated protein kinase A (PKA) binds
cAMP responsive binding element (CREB) stimulating gene transcrip-
tion of UCP1. Secondly, PKA can directly stimulate lipolysis by acti-
vating hormone sensitive lipase (HSL) leading to the release of fatty
acids from the intracellular lipid droplet. These intracellular released
fatty acids also stimulate UCP1 [11]. Besides the essential sympathetic
activity, other factors influence BAT activity as well. CREB stimulates
transcription of iodothyronine deiodenase 2 (DIO2), which stimulates
intracellular conversion of inactive thyroid hormone T4 to active
thyroid hormone T3 [11]. Optimal BAT thermogenesis depends on in-
tracellular levels of T3 [14,15], which explains the association between
hypothyroidism and lower body temperature and the feeling of cold
[16].
UCP1 is a requisite for uncoupling in adipocytes, however UCP1
expression is not always similar in thermogenic adipocytes found in
different adipose tissue depots. In rodents, the presence and activity of
BAT is a well-known and studied fact [17]. In these animals, the in-
terscapular depot is most recognized for the presence of brown adipo-
cytes [2]. These brown adipocytes are usually referred to as constitutive
or classical brown adipocytes (cBAT). These cBAT cells are UCP1 po-
sitive, even without cold stimulation. Furthermore, classical brown
adipocytes are myogenic factor 5 (myf5) positive indicating a similar
lineage as skeletal muscle [18]. Peroxisome proliferator activated re-
ceptor gamma coactivator 1 alpha (PGC1a) is known as an important
regulator of mitochondrial biogenesis and plays a crucial role in adi-
pogenesis of thermogenic adipocytes. Next to that PGC1a is able to
activate the UCP1 gene in BAT [19]. PGC1a target PR domain zinc
finger protein 16 (PRDM16) is a key element in differentiation of brown
adipocytes in mice and humans. Indeed, knock down of PRDM16 in
precursor cells for brown adipocytes, redirected differentiation in the
direction of muscle cells [20]. In addition, in PRDM16 knockout mice,
the BAT depots showed clear signs of whitening [21]. Upon cold ex-
posure, the white adipose tissue depots, showed no sign of compensa-
tory browning. The adipose cells in knockout mice contained very few
mitochondria, with less mitochondrial organisation then in wild type
mice [21]. During cold exposure the knockout mice had a larger drop in
core temperature then wild type mice, and total body energy con-
sumption upon NE exposure was clearly depressed in the knockout
mice. All in all these results show the importance of PRDM16 in the
regulation of BAT in mice [21].
Cold exposure in rodents can transform the adipocytes in WAT. The
discovery of recruitable adipocytes was already reported in 1984 in
rodent WAT following cold [22]. These changes include, among others,
increased mitochondrial biosynthesis and expression of UCP1, enabling
a shift towards a brown adipocyte phenotype [23]. These recruitable
adipocytes appeared to be from a myf5 negative lineage and are re-
ferred to as beige or brite (=brown in white) adipocytes [20,23].
Histology clearly shows presence of these recruitable adipocytes in
WAT following prolonged cold exposure [24]. Though originally from
different lineages, classical brown adipocytes and recruitable adipo-
cytes have similar cellular structure. Both possess paucilocular fat
droplets and multiple mitochondria [24,25]. Both also show strong
activation upon cold exposure [24] as both types use UCP1 to uncouple
ATP production to produce heat.
In mice, the development of these recruitable brown adipocytes is a
genetically controlled process because certain mouse strains display
major increases in UCP1 expression in WAT following cold stimulation
while others do not [26]. Furthermore in a knockout model, mice
without cBAT compensate this loss by developing recruitable BAT [17].
There are also strong indications that britening and whitening occurs
through a direct interconversion of a white adipocyte into a brown
adipocyte phenotype, a process referred to as transdifferentiation, in
which the earlier mentioned PDRM16 plays an important role [21,27].
The main difference between cBAT and recruitable adipocytes is the
presence of UCP1. In cBAT, UCP1 is always present, while in recruitable
adipocytes UCP1 is upregulated following appropriate stimulation like
cold exposure.
In adult humans, biopsy material does not always resemble cBAT as
seen in rodents. Biopsies of human BAT are UCP1 positive in adults and
infants [6–8,28], however it has been suggested that adipocytes in adult
human BAT are more of a recruitable nature compared to classical
brown adipocytes [24,29]. Furthermore it is not known whether myf5
positive UCP1 positive adipocytes are present in humans. The sugges-
tion that murine recruitable adipocytes are derived from a smooth-
muscle like origin [30] might also hold true for human brown adipo-
cytes.
While cBAT in rodents persists with ageing [2], BAT in humans
seems to dissipate in the elderly [31]. BAT activity is also lower in obese
subjects, with an improvement after weight loss [32]. However re-
cruiting BAT is a proven concept, both in obese and older human
subjects [33–35]. These studies lead to the conclusion that recruiting
BAT is a distinct possibility to influence energy metabolism in humans.
We will discuss measuring BAT activity in humans below in Section 3.
2.2. Markers for BAT
Although the composition and origin of BAT in humans is still under
debate, it is evident that the adipocytes in human BAT are UCP1 po-
sitive and that these cells have the potential of norepinephrine and
cold-stimulated thermogenesis [36]. It should be noted that BAT in
mouse and man cannot simply be compared. Many publications are
dedicated to identify molecular markers in order to distinguish ther-
mogenic adipocytes [24,37–40]. Although UCP1 is the right marker of
choice when examining brown and recruited adipocytes, it might not be
the most practical marker, because it is located inside the mitochondria.
Therefore the scientific community has been looking for other markers
aimed to identify UCP1 positive adipocytes that are preferentially ex-
pressed at the cell surface, in order to easily extract these cells via cell
sorting experiments that could aid to further elucidate the origin of
recruitable adipocytes in humans. Also in general, the discovery of
novel markers of UCP1 positive adipocytes could help in drug devel-
opment to enhance thermogenesis. It is not our goal to review all
markers associated with BAT identity (for review see [41]). Here we
present a selection of the most recently discovered molecular markers
with high potential aimed to identify UCP1 positive adipocytes in hu-
mans, as shown in Fig. 1. The discussed markers can either be targeted
by pharmacological means or they provide novel insights into BAT
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origin and physiology.
As mentioned earlier BAT is dependent on norepinephrine release
from the sympathetic neuron. Following norepinephrine release, it
binds β3 adrenergic receptor thereby activating BAT. The uptake of
norepinephrine in adipocytes is inhibited by cell membrane transporter
organic cation transporter 3 (OCT3). This transporter is able to shuttle
various hormones across the cell membrane. Although ubiquitously
expressed [42], higher expression can be detected in deep neck adipose
tissue compared to human subcutaneous WAT [43]. OCT3 function can
be inhibited by corticosterone [43]. This opens pathways for future
venues to develop pharmacological intervention directed to OCT3 that
could stimulate human BAT activity.
The PAT2 gene encodes a pH dependent proton/amino acid trans-
porter that is selective for small chain amino acids [44]. The transcript
for this gene was detected primarily in skeletal muscle and kidney [45].
When it comes to adipose tissue, PAT2 expression is specific for human
BAT compared to subcutaneous WAT [46], however PAT2 was not
detected in brown-like/recruitable adipocytes from children in WAT
[47] although these samples were UCP1 positive. With an eye towards
the future, PAT2 is a valuable marker to detect adipocytes that express
UCP1. Because PAT2 is a cell surface expressed protein, this gives
openings to isolate cells via cell sorting.
Purinergic receptor P2X, ligand-gated ion channel 5 (P2RX5) be-
longs to a family of extracellular ATP-gated ion channels. The ion
channel localizes to the cell membrane and its expression is high in
immune system and brain [48]. P2RX5 is sensitive to changes in ex-
tracellular concentrations of calcium [49]. In adipose tissue, P2RX5
shows specificity towards human BAT over subcutaneous WAT [46]. In
mice, P2RX5 is expressed in murine brown preadipocytes and its ex-
pression is further increased during adipocyte differentiation. Further-
more, expression of P2RX5 was increased following cold stimulation in
mice in both BAT and subcutaneous WAT [46] similar to the response
as UCP1.
Mitochondrial tumor suppressor 1 (MTUS1 also known as ATIP) is a
mitochondrial protein that controls cellular proliferation [50]. MTUS1
expression is higher in human BAT compared to WAT. MTUS1 ex-
pression can be regulated via cold, because human BAT biopsies after
prolonged cold exposure showed an increase in MTUS1 [51]. Knock-
down of MTUS1 in human cultured brown adipocytes resulted in re-
duced UCP1 expression and decreased mitochondrial uncoupling sug-
gesting a role in BAT thermogenesis [51]. Interestingly in mice,
overexpression of MTUS1 resulted in reduced inflammation, less re-
cruitment of macrophages and increased insulin sensitivity in WAT
[52]. These findings in WAT might suggest that BAT might handle an
inflammatory insult better resulting in normal metabolism.
KCNK3 (also known as TASK) encodes a pH sensitive potassium
channel, subfamily K, member 3 [53]. Expression of KCNK3 is specific
to human BAT compared to human WAT [51,54], and KCNK3 expres-
sion shows a negative correlation to age or BMI in human BAT [55].
The amount of KCNK3 is correlates with PRDM16 [51,56]. KCNK3
negatively affects second messenger signalling of the beta-adrenergic
receptor via cAMP [56]. KNCK3−/− mice are obese and their brown
adipocytes show resistance at the level of activation of the beta-adre-
nergic receptor [56]. Furthermore the explanation for this phenotype
was through enhanced mineralocorticoid receptor signalling, which
could be targeted by inhibitor eplerenone [56]. KCNK3 is an interesting
marker to identify BAT, which in the future could result in novel
methods to stimulate BAT in humans.
Adenosine, is product of ATP breakdown, however it can also act as
a signalling molecule via interaction with adenosine and purinergic
receptors. Adenosine stimulates in vitro BAT activity and this stimula-
tory effect is further enhanced by adrenergic stimulation. More specific,
an agonist for the A2A receptor markedly increased in vitro BAT ac-
tivity. In murine experiments stimulation of BAT with norepinephrine
results in release of adenosine further linking adenosine to BAT activity
[57]. Novel ligands have been designed to target the A2A receptor (for
review see [58]), however it remains to be seen how these compounds
can affect human BAT activity.
2.3. Summary/take home message
Contrary to many rodent species, adipocytes detected in adult
human BAT biopsies are mostly of a recruitable nature (beige or brite
adipocytes) [24]. Characterisation of these recruitable brown adipo-
cytes can be useful to better understand the origin of these adipocytes
and to ultimately devise new strategies to stimulate thermogenesis in
humans. Earlier attempts to characterize these recruitable BAT cells
were built upon the use of genetic and intracellular markers, which
often gave inconclusive results. Several new markers with high poten-
tial have been discovered in the recent past, especially to detect these
BAT cells using cell membrane specific markers. These new markers
focus on activation of BAT cells using different interventions.
3. Brown adipose tissue activation and detection in humans
3.1. BAT activity stimulation besides cold exposure
Besides cold exposure, pharmacological stimulants have also been
tested in humans. A non-selective systemic beta-adrenergic stimulation,
by isoprenaline [59] and ephedrine [60] did not show significant ac-
tivation in BAT glucose uptake and resulted in negative cardiovascular
side effects [59]. More promising results are found in the use of a se-
lective B3 stimulant, mirabregon. This showed an elevated uptake in
BAT upon stimulation [61] comparable to cold activation. However the
needed dosage and potential side effects are still matter of debate.
Systemic administration of pharmacological stimulants is not selective
for BAT only, as it also affects other tissues, such as white adipose
tissue.
The suspected relationship between BAT activity in humans and
β3 receptor
UCP1 
Norepinephrine
OCT3
PAT2
P2RX5
MTUS1
KCNK3
Cold exposure
Fig. 1. Overview of discussed recently identified cellular markers for human
brown adipocytes. In the central pathway, cold exposure acting through nor-
epinephrine on the β3 receptor is shown, resulting in increased UCP1 expres-
sion. UCP1 (uncoupling protein 1); OCT3 (organic cation transporter 3); PAT2
(proton/amino acid transporter 2); P2RX5 (purinergic receptor P2X, ligand-
gated ion channel 5); MTUS1 (mitochondrial tumor suppressor 1); KCNK3 (pH
sensitive potassium channel, subfamily K, member 3).
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diet-induced thermogenesis (DIT) has also been an interesting topic. As
reviewed by Kozak [62], the theory that excessive energy with food
intake is expended as heat through BAT activation has not been proven.
Vosselman et al. [63] compared BAT activity after meal consumption
with cold exposure. They found that the amount of BAT activity did
increase after large meal consumption, however there was no re-
lationship with DIT.
BAT may still be stimulated through certain dietary components
such as components in green tea (cathechin-polyphenols and caffeine),
peppers (capsinoids) and menthol [64,65]. Green tea extract contains
cathechin-polyphenols, which are able to inhibit catechol-O-methyl-
transferase, the enzyme responsible for the breakdown of sympathically
released norepinephrine. The caffeine, present in green tea extract, is
believed to inhibit phosphodiesterase, which in turn breaks down the
cAMP second messenger system. Furthermore, caffeine also acts as
antagonist on adenosine receptors (see above). Green tea extract could
thus be used to potentiate the adrenergic and/or via adenosine path-
ways and thus lead to more BAT activation [65].
The pungent capsaicinoids, found in peppers are able to stimulate
BAT activity via the transient receptor potential channels (TRPV) [64].
Stimulation of TRPV channels in the brain would lead to more sym-
pathic activity and in turn to increased BAT activity. However the
strong pungency, may lead to reduced intake or gastro-intestinal side
effects [66]. The non-pungent forms, known as capsinoids, have been
studied in their potential to stimulate BAT [67]. However, this study
only showed a higher increase in energy expenditure upon cold ex-
posure in BAT positive subjects compared to BAT negative subjects
using capsinoids.
Another recently discovered potential stimulant in humans is sil-
denafil. Sildenafil is a well-known phosphodiesterase type 5 (PDE5)
inhibitor, commonly used to treat erectile dysfunction in men. By in-
hibiting PDE5, it can elevate levels of cGMP via guanylyl cyclase, which
in turn can further stimulate lipolysis in BAT cells. Sildenafil was shown
to induce browning in human WAT [68], and could thus be an inter-
esting target for study in humans.
As seen in earlier studies, the direct stimulation of soluble guanylyl
cyclase has already shown to increase whole-body energy expenditure
and lipid uptake in BAT in mice, as well as inducing browning of
murine white adipocytes [69,70]. This makes increasing cGMP an in-
teresting potential target for BAT stimulation.
3.2. Measurement of BAT activity in humans
In order to determine the role and the contribution of BAT to whole
body metabolism in adult humans, quantitative measurements of BAT
activity are needed. The rediscovery of the presence of active BAT in
humans was accomplished by positron emission tomography/computed
tomography (PET/CT) scan with a radioactive labelled glucose tracer,
18-Fluor-Deoxy-Glucose (18F−FDG) [6–8]. Ever since, the 18F−FDG-
PET/CT technique has been the most used test for detecting the pre-
sence of BAT in humans. Alternatively, some studies use other substrate
tracers such as 18-Fluor 6-thia-heptadecanoidic acid (18F-FTHA) as a
marker for fatty acid uptake.
Besides substrate uptake, several other aspects of BAT activity can
be measured such as oxidative metabolism, local blood perfusion and
sympathic innervation. In the following we will discuss the usefulness
of some of these techniques to quantify the contribution of BAT to
whole body metabolism (Table 1). For a more exhaustive review of
these techniques and tracers we would like to refer to Bauwens et al.
[71] and Chondronikola et al. [72].
In Fig. 2, we provide a visual overview of these methods.
3.3. Skin temperature
Since active BAT releases energy in the form of heat, one way of
measuring this energy is by looking at the temperature around the BAT
depots.
As BAT is active and releases heat, one can expect the temperature
around the depot to increase. Measuring the skin temperature via
thermometers or wireless sensors has been used before, while using the
18F−FDG PET/CT as benchmark [76]. This study by Boon et al. showed
a positive correlation between supraclavicular skin temperature upon
cold exposure and BAT volume and activity.
Another option is the use of thermal imaging. Via an infrared
thermal camera, it is possible to measure the temperature of a larger
part of the skin's surface.
It is a quick and easy technique, without radiation exposure or in-
vasive actions [75]. Several studies showed a significant correlation
between BAT activity on 18F−FDG PET/CT and the changes in supra-
clavicular skin temperature [73,76,77]. The changes in the supracla-
vicular skin temperature are not consistent, which may be because of
the different cooling techniques, air-cooled vs. water-cooled respec-
tively affecting the skin temperature differently [73].
The downside is that the increase in skin temperature at the cervical
depots is off set by the cold exposure used to stimulate BAT. It is
therefore difficult to estimate the amount of heat produced by BAT.
Furthermore, the infrared thermal imaging and skin temperature do not
measure the heat production in the deeper depots [75]. The amount of
subcutaneous fat at the cervical region may also hinder the adequate
measurement of the effect of BAT on the skin temperature [96,97].
In conclusion: while this technique is non-invasive and is without
radiation exposure, it is an imprecise and indirect measurement. At best
it is a qualitative approach.
3.4. Measuring substrate uptake
The details behind positron emission tomography are well discussed
in technical literature [98,99]. In short, a so-called tracer is injected
into the subject, after which the tracer will distribute inside the body.
Tracers usually consist of a substrate with an attached radioactive
Table 1
Overview of different measurements of BAT activity.
Measurement of BAT aspect Quantitative analysis
possible?
Temperature
Skin temperature [73–77] No quantitative analysis,
only surface temperature
Indirect and imprecise
Substrate uptake tracers
18-Fluor 6 deoxyglucose [6–8,35,61,78–80] Yes, glucose uptake rate
18-Fluor 6-thia-
heptadecanoidic acid
[80–83] Yes, fatty acid uptake
rate
Adrenergic innervation
123-Iodine meta-iodo-
benzylguanidine
[84–87] No quantitative analysis,
sympathic innervation
18-Fluor-L-
dihydroxyphenylalanine
[88] No quantitative analysis,
sympathic innervation
Oxidative metabolism tracers
Acetate [80,82] No quantitative analysis,
oxidative metabolism
15-Water [89,90] Yes, blood perfusion
15-Oxygen [89,91] Yes, oxygen consumption
Additional techniques
CT scan (Hounsfield units) [81] No quantitative analysis,
changes in BAT density
MRI scan [92,93] Changes in BAT water/
fat fractions, potential of
measuring metabolic
processes
Exosomal miRNA [94,95] Associated with BAT
activity in healthy
subjects
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component. The most well known tracer is 18F−FDG (18-fluor deoxy-
glucose). This consists of glucose, with an attached 18-fluor atom. Like
normal glucose, this 18F−FDG undergoes uptake by glucose transpor-
ters [100,101]. However, 18F−FDG is then only metabolized to 18F-
FDG-6-phosphate, as the next step in the glycolysis does not happen to
FDG. This is due to the fact that the enzyme responsible for the next
step, glucose-6-phosphate isomerase is unable to convert FDG-6 phos-
phate. The reverse conversion of 18F-FDG-6-phosphate to 18F−FDG is
not possible due to low levels of the necessary enzymes. The 18F−FDG
remains therefore trapped inside the cell, and is only slowly broken
down by other pathways [100,101]. As the PET image only shows tissue
tracer uptake, another technique is necessary to correlate the positron
emission with an anatomical image.
A regular computed tomography, is often performed together with
the PET capture. This will provide a detailed anatomical scan, allowing
a correlated image. The 18F is an unstable isotope of the Fluor atom, and
will decay into 18O, with concomitant release of energy. This released
energy will be in the form of positrons, which is measured on a sensor
outside the body. The 18F−FDG is mainly trapped and visualized in
those tissues of the body that take up glucose, such as the brain, the
heart under specific conditions, tumours, and activated BAT.
In the case of brown adipose tissue, the tracer is often administered
after and during cold exposure. During the distribution phase, the tracer
will localize to the active BAT, if present in the subject. Most tracers are
usually used in a static scan, while BAT is a highly dynamic tissue. To
measure tissue substrate uptake rate, a dynamic scan method can be
used. A dynamic PET/CT, using Patlak curve [102,103] fitting reveals a
measure of glucose uptake rate [35].
For comparison between studies the followed procedures of the
combined PET/CT (or PET/MR) requires clear descriptions and
preferably standardization. In the so-called BARCIST (Brown Adipose
Reporting Criteria in Imaging Studies) publication, an expert panel,
assembled by the National Institutes of Diabetes and Digestive and
Kidney diseases on November 4, 2014, wrote guidelines and sugges-
tions for determining BAT activity in 18F−FDG PET/CT scans [104]. A
main guideline states that determining the activity of BAT should be
presented using standardized uptake values (SUV). The SUV is calcu-
lated as the ratio between the measured radioactivity of the tracer
within a region and the dosage of the administered tracer relative to the
body weight [104]. This makes comparing the results in repeated
measurements or across different subjects possible. However, the sub-
ject characteristics, such as BMI (body fat percentage) influence the
distribution of the tracer and therefore the SUV in the target tissue
[104]. For instance, obese subjects less 18F−FDG uptake is seen in BAT
depots, which may be related to a competition with the WAT depots. It
may therefore be more applicable to calculate the SUV value as the
tracer dosage relative to the lean body mass. Other subject character-
istics to take into account are medications, which influence the sym-
pathic nervous system, smoking habits and dietary components such as
capsinoids [61]. There is still some uncertainty regarding the fate of the
18F−FDG once taken up and trapped by the BAT cells. It is unknown if it
undergoes intracellular metabolism or if it excreted after a certain time
period. In diabetic subjects the insulin resistance in these subjects, may
lead to less uptake and trapping of 18F−FDG in the cells.
Besides the methodological variation, there is also the biological
variation of BAT to take in to account. The outdoor temperature and
climate also influence the analysis of BAT, as a cold climate or outdoor
temperature may stimulate BAT activity and lead to increased BAT
volume. Studies regarding cold acclimation and weight loss have shown
to increase BAT volume and activity [13,63,104].
Norepinephrine
Substrate uptake
18F-FDG
18F-FTHA
Sympathic innervaon
123I-MIBG
18F-DOPA
Oxidave metabolism/ 
blood flow
15O-H2O
15O-O2
11C-Acetate
Heat producon
Skin temperature
ETC
miRNA
UCP1 
β3 receptor
Exosomes
Fig. 2. Overview of the different measurement techniques for brown adipose tissue activity, as discussed in the text. Centrally shown is cold exposure acting via
norepinephrine on the β3 receptor. This in turn leads to increased UCP1 expression, resulting in heat production. ETC (electron transport chain); UCP1 (uncoupling
protein 1); 18F-FDG (18-Fluoro-Deoxy-Glucose); 18F-FTHA (18-Fluoro 6-thia-heptadecanoidic acid); 123I-MIBG (123-Iodine meta-iodo-benzylguanidine); 18F-DOPA
(18-Fluoro-Ldihydroxyphenylalanine).
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FDG accurately reflects the capacity of tissue to take up glucose and
is used as a standard diagnostic tool in cancer patients. However, FDG
does not directly reflect the energy expenditure of BAT, where fatty
acids (external and internal stored) are the main source of energy [1].
This can have important consequences for the interpretation of results,
potentially leading to an underestimation of BAT energy metabolism.
Indeed, use of different tracers show that depending on the type of
tracer the interpretation of the results (for instance the contribution of
BAT to whole body energy expenditure) is different [89,91].
Beyond FDG several alternative tracers - such as 99mTc-sestamibi,
123Imetaiodobenzylguanidine (MIBG), 18F-fluorodopa, perfusion and
oxygen consumption studies but also 18F-14(R,S)-FTHA - have been
employed for BAT imaging [71]. Fatty acids metabolism (exemplified
by FTHA uptake) may be less hampered by associated disturbances in
glucose metabolism than FDG uptake in metabolic syndrome. Still for
quantification, the use of FTHA may be difficult, because internal
brown adipocyte fat stores are also used as fuel during BAT activation.
Besides anatomical information the CT scan can also be used to
register BAT activity. CT measures the density of the tissues, which is in
the first place used to discriminate between BAT and WAT. However
during BAT activation, internal fat stores may be used which affects the
density of the BAT. If the density is measured before and after an in-
tervention (for instance cooling), the decrease in density can be used to
estimate the lipids combusted by the active BAT [81].
Alternatively, magnetic resonance (MR) scan can be used to make
an anatomical scan, instead of a CT scan. This technique allows for
highly detailed anatomical information, without the extra radiation
exposure a CT scan requires. PET/MRI systems become more widely
available. Moreover MRI (Dixon technique) can be used to determine
the changes of the fat fraction in tissues that may reflect metabolic
activity. Next to monitoring the fat fraction by Dixon MRI, the use of 1H
Magnetic Resonance Spectroscopy (1H-MRS) can be used to follow
metabolic changes in activated BAT (for instance NAD+ precursor ni-
cotinamide riboside) [93]. Future studies are needed to reveal the ap-
plicability.
3.5. Adrenergic innervation
Another option is to measure the adrenergic innervation using 123-I
meta-iodo-benzyl guanidine (123I-MIBG) as tracer. This tracer binds to
the adrenergic receptors present on cells, and could thus be used to
determine the amount of adrenergic stimulation in BAT. This tracer has
been used in diagnosing pheochromocytomas and other tumours of
adrenergic origin [86,87]. One study combined 18F-FDG-PET/CT with
MIBG-SPECT, which showed that both tracers show uptake in the same
cervical regions [84], which would then be determined as BAT tissue.
Another option is to use 18-Fluor-L-dihydroxyphenylalanine (18F-
DOPA) as a tracer. This tracer is used in the same capacity as 123I-MIBG,
and only a case report describes the use of 18F-DOPA in measuring BAT
tissue [88]. Although capable of measuring the sympathic innervation
of BAT tissue, for the quantification of the contribution of BAT to whole
body metabolism these tracers are not useful.
3.6. Oxidative metabolism tracers
The amount of blood flow to BAT can be measured using 15O la-
belled water (15OeH2O), as well as the oxygen consumption via an
oxygen-tracer (15OeO2). Only a few studies used these techniques and
found that subjects with FDG uptake in the cervical region did have
increased blood flow and oxygen consumption [89,90]. However the
estimated contribution of BAT to the total energy expenditure is small
about 5% of the total energy expenditure [89].
The major issue is that 15O has an extremely short half-life of about
2min [92]. This in combination with the rapidly diffusing isotope and
the limited field of view that can be studied with this technique may
lead to an underestimation of the BAT activity. The currently available
studies also show the need for well attuned cooling procedures and the
PET/CT procedure [89,91].
Another option to measure BAT oxidative metabolism is to use 11-
Carbon Acetate (11C-Acetate) during dynamic scanning. This tracer is
labelled with the 11-C isotope, and undergoes uptake in active tissues.
Studies using 11C-Acetate have shown a significant oxygen metabolism
of human BAT, [80,82]. The use of these tracers might actually give the
most direct measurement of BAT activity, as they measure the oxidative
capacity of BAT.
The short half-life of tracers such as 15OeO2, are issues that would
need to be resolved, before they could be used to accurately quantify
BAT energy consumption.
3.7. Exosomal miRNA
As published by Chen et al. in 2016 and Ng et al. in 2017, several
micro RNA sequences (miRNA's) have been found in association with
BAT activity [94,95]. Chen et al. analysed serum from both murine
brown adipocytes as well as from cultured human brown adipocytes.
They found several miRNA's to be expressed differently. One of these
miRNA's, miRNA-92 inversely correlated with BAT activity in young
healthy subjects, as measured via PET/CT [94]. Ng et al. describe an-
other miRNA, miRNA 32, to be involved in the response of adipocytes
to cold stress. After cold stress increased levels of miRNA-32 were as-
sociated with browning of white adipocytes, and increased levels of
browning markers such as PGC1α and increased expression of UCP1
[95].
Further evaluation of the use of miRNA's is needed, but the results
are promising. The great advantage of this method would be in mea-
suring BAT activity via blood sampling, and would possibly render the
use of nuclear imaging and the radiation exposure superfluous.
4. Contribution of BAT to total body energy expenditure
In a normal human, the total body energy expenditure (TEE) can be
divided in to different components: 1) energy expenditure during sleep
(sleeping metabolic rate, SMR), 2) resting energy expenditure during
arousal (Basic metabolic rate, BMR), 3) diet-induced energy ex-
penditure (DEE) and the energy expenditure during activity (AEE)
[105,106]. Diet-induced thermogenesis (DIT) can be divided into an
obligatory and a facultative component [107]. The obligatory compo-
nent is the energy expended to consume, digest and metabolize food,
while the facultative component depends on the composition and
amount of food consumed [105,108].
The energy expenditure also increases during cold exposure, as the
body is stimulated to maintain a stable core temperature. This ther-
mogenesis can in turn be divided in two parts: shivering and non-shi-
vering [109]. Shivering thermogenesis refers to the involuntary muscle
contractions, which organisms show upon cold exposure. These con-
tractions occur quickly upon cold exposure and generate heat in an
effort to maintain a stable core temperature. Non-shivering occurs
mainly in BAT, and is a process requiring adaptation [109].
In order to measure the NST and potentially indirectly BAT activity
indirect calorimetry is normally used: the analyses of inhaled and ex-
haled air. By this means O2 consumption and CO2 production can be
determined and the amount of energy expended in time can be calcu-
lated [110]. When using this technique during both resting and cold
exposure, the increase in energy expenditure upon cold exposure, the
NST can be calculated. It appears in many studies that NST strongly
correlates with BAT activity measured via 18F-FDG PET/CT [7,35].
However the contribution of activated BAT to whole body energy
expenditure is still not established. In animals, especially rodents, the
role of BAT is more clear-cut than in humans. The studies using tracers
15OeO2, which actually measure oxygen usage have all shown that the
overall contribution of BAT to total energy expenditure comes down to
about 1–5% of resting metabolic rate (RMR) [89,91]. Though very
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interesting experiments, these measurements are hampered by the short
half life of the isotopes of 2min, the rapidly diffusing isotope and the
use of a limited field of view (only a small part of the body is actually
scanned). The authors therefore conclude that the activity of BAT may
be underestimated. Their results are lower than based on an earlier
estimation of BAT contribution using BAT metabolic rate from rodents
and allometric comparison, as done by Van Marken Lichtenbelt and
Schrauwen [107]. Their calculation revealed an estimation of 5% of
RMR. The data of the study of van der Lans et al. [35], who performed a
dynamic 18F-FDG PET/CT scan, show that glucose uptake rate varied
substantially between subjects, from almost zero to more than 25 μmol/
g BAT. When using these numbers maximal BAT activity comes up to
16% of RMR and almost 90% of NST.
Although the current contribution of BAT is still a matter of dispute
in humans, the potential of BAT can be significant. All current studies to
increase BAT focus on a short period of exposure to cold (cold accli-
mation) or pharmacological stimulation.
Cold acclimation, even as short as 10 days has shown to increase
BAT activity and volume [35]. As seen in different acclimation studies,
the energy expenditure of BAT increases after acclimation, as well as
the oxidative capacity [35,80,111]. A more recent study by Leitner
et al. showed that FDG-uptake upon cold exposure also occurs outside
of the classical BAT depots [10]. They also show the 18F-FDG uptake in
a patient with a paraganglioma with a long exposure to high levels of
adrenergic hormones. This shows 18F-FDG uptake in the perirenal and
subcostal WAT depots. This would mean that potentially these regions
could be stimulated to develop BAT-like properties. Estimated by
Leitner et al. a maximum of 115.5 kcal/d could be produced by the
entire BAT volume [10].
This estimation would lead to the conclusion that most studies thus
far, have only shown an under appreciation of brown adipose tissue. A
stronger or longer exposure to cold or pharmacological stimulants could
lead to a much larger contribution of BAT to energy expenditure. The
effect on metabolic health in that regard could be significant. Earlier
studies have shown some effects on lipid and glucose metabolism,
[78,81] but a much more profound effect on metabolic health would be
a welcome sight.
In order to maximize the effect of BAT, more exposure to cold would
be desirable. However most studies have used a temperature of around
14–16 degrees Celsius, which is often not appreciated by subjects. A
prolonged exposure to a less cold environment, may be a potential
solution. New research should not only focus on finding new stimulants
for BAT, but also on increasing the potential of BAT in humans.
Although increasing energy expenditure can influence the energy
balance, potential compensation can occur by increased food intake.
This could lead to attenuation of beneficial effects of increased energy
expenditure on health and metabolism. There are indications that not
all of the increase in energy expenditure is compensated [112].
Another issue is the potential negative consequence of a prolonged
increase in energy expenditure in obese subjects. Several observational
studies showed that obese subjects with heart failure might have a
better prognosis then lean subjects with heart failure [113,114]. This
so-called obesity paradox indicates that increasing energy expenditure
to combat obesity should be closely observed for long-term cardiovas-
cular side effects. In this case, the goal should be weight maintenance
and not decrease of body weight.
To conclude, brown adipose tissue remains an interesting and pos-
sibly underestimated target in metabolic health. It still needs further
exploration to what extent BAT activation can become a new treatment
for obesity and it's complications.
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